HMR code: 26-501
| ISRCTN | ISRCTN72347535 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN72347535 |
| Integrated Research Application System (IRAS) | 1014425 |
| Sponsor | ALLInBio, Inc. |
| Funder | ALLInBio, Inc. |
- Submission date
- 10/11/2026
- Registration date
- 18/11/2026
- Last edited
- 18/11/2026
- Recruitment status
- Not yet recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date.
Contact information
Public, Scientific
ALLInBio, Inc. 3160 Porter Driver, Suite 200
Palo Alto, CA
94304
United States of America
| Phone | +1 415-725-6030 |
|---|---|
| clinicaltrials@allinbio.com |
Principal investigator
Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, Park Royal
London
NW10 7EW
United Kingdom
| 0009-0007-3133-5152 | |
| Phone | +44 (0)20 8961 4130 |
| rec@hmrlondon.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | Randomized controlled trial |
| Masking | Blinded (masking used) |
| Control | Placebo |
| Assignment | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Purpose | Phase I trial in healthy participants |
| Scientific title | HMR code: 26-501 Full scientific title to be added on or before the deferral expiry date |
| Study objectives | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Ethics approval(s) |
Submitted 21/09/2026, London – Brent Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8129; brent.rec@hra.nhs.uk), ref: 26/LO/0478 |
| Health condition(s) or problem(s) studied | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Intervention | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Completion date | 02/06/2028 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 80 Years |
| Sex | All |
| Target sample size at registration | 148 |
| Key inclusion criteria | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Key exclusion criteria | The sponsor has requested a deferral. The full details will be added to the trial record on or before the deferral expiry date. |
| Date of first enrolment | 30/11/2026 |
| Date of final enrolment | 16/08/2027 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
London
NW10 7EW
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
17/11/2026: Trial's existence confirmed by MHRA.